Wedbush maintains Zura Bio at Outperform, lowers price target to $10 from $22

Wedbush kept Zura Bio's rating at Outperform but reduced its price target from $22 to $10, a 54.5% cut. This implies a 144.5% upside from the Nov 6 close of $4.09, according to the firm.

Original reporting
Published Nov 9, 2026, 5:27 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 5:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Wedbush maintains Zura Bio at Outperform, lowers price target to $10 from $22 — source image
Decision brief

The 30-second read

$ZURABearishMed
01

Why it matters

Analyst target reduction reflects concerns about near-term growth prospects, likely prompting short-term price weakness.

02

Market read

The downgrade may trigger a sell-off in ZURA and influence sentiment in the broader biotech sector.

03

What to watch

Potential upcoming clinical data or partnership announcements could offset the downgrade.

Relevance 5/10Novelty 5/10Timing: today

Background

Zura Bio (NASDAQ: ZURA) is a clinical-stage biotech focused on oncology therapies.

Company-level read

Ticker impact

$ZURABearishHigh confidence
Context

Wedbush lowered Zura Bio's price target from $22 to $10, indicating a significant downgrade.

Expected impact

likely downward pressure as investors price in the reduced target

Evidence & confidence

Analyst downgrade with a 54.5% target reduction signals weaker expectations for the stock.

Market effects

May weigh on other small-cap biotech stocks as analysts reassess valuations.

Limited to US biotech sector.

Low, confined to niche biotech investors.

Counterpoint

Some investors may view the cut as an overreaction and see buying opportunity at the lower target.

Key entities

  • Wedbush Securities

    Provided the rating maintenance and target cut.

  • Zura Bio Inc.

    Subject of the analyst downgrade.

Related articles

$ZURAMedAI 8/10

Zura Bio Discontinues Tibulizumab Development In Hidradenitis Suppurativa After Phase 2 Setback

Zura Bio (ZURA) halted development of tibulizumab for hidradenitis suppurativa after its Phase 2 trial failed to meet primary and key secondary goals. Both doses showed similar reductions in abscesses and inflammatory nodules compared to placebo. The company will continue developing the drug for systemic sclerosis and polymyalgia rheumatica. ZURA had $187.7M in cash as of September 30, 2026, and its stock is down 72.24% to $1.13.

$ZURAHighAI 8/10

Why is Zura Bio stock collapsing today?

Zura Bio's stock fell 68.2% after its Phase 2 trial for tibulizumab in hidradenitis suppurativa failed to meet primary and secondary endpoints. The company halted development for this indication, leaving two other trials in its pipeline. Zura Bio has $187.7M in cash, expected to last until 2028, but the market reacted negatively to the setback.